Showing results (1-10 of 79) with videos related to
Sort By:
Pageof 8
Plos One|May 2, 2015
Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase InhibitorsAnne Leinonen, Marjaana Koponen, Sirpa HartikainenBMC Geriatrics|June 20, 2020
Length of hospital stay after hip fracture and readmission rates of persons with and without Alzheimer's disease: a matched cohort studyBlair Rajamaki, Marjaana Koponen, Sirpa Hartikainen, et al.European Journal of Clinical Pharmacology|January 16, 2020
Use of antidepressants and mood stabilizers in persons with first-episode schizophreniaArto Puranen, Marjaana Koponen, Antti Tanskanen, et al.Parkinsonism & Related Disorders|September 5, 2022
Incidence of antipsychotic use among community dwellers with and without Parkinson's diseaseSatu Lilja, Anna-Maija Tolppanen, Marjaana Koponen, et al.BMC Geriatrics|November 3, 2020
Causes of death in a nationwide cohort of community-dwellers with Alzheimer's diseaseAnna-Maija Tolppanen, Heidi Taipale, Marjaana Koponen, et al.Clinical Epidemiology|November 3, 2022
Identification of Drugs Associated with Lower Risk of Parkinson's Disease Using a Systematic Screening Approach in a Nationwide Nested Case-Control StudyMarjaana Koponen, Anne Paakinaho, Julian Lin, et al.Basic & Clinical Pharmacology & Toxicology|September 29, 2025
The Incidence of Benzodiazepine and Benzodiazepine-Related Drug Use in People With and Without Parkinson's Disease-A Nationwide Cohort StudyVeera Lonka, Sirpa Hartikainen, Miia Tiihonen, et al.Journal of the American Medical Directors Association|November 20, 2022
Recent Hospitalization and Initiation of Antiepileptics Among Persons With Alzheimer's DiseaseJenna Elo, Anna-Maija Tolppanen, Marjaana Koponen, et al.British Journal of Clinical Pharmacology|April 4, 2026
Psychotropic medication use among community dwellers with and without Parkinson's disease - A nationwide cohort studyNoora Nieminen, Anna-Maija Tolppanen, Valtteri Kaasinen, et al.Acta Psychiatrica Scandinavica|September 6, 2022
Real-world effectiveness of mood stabilizer use in schizophreniaArto Puranen, Marjaana Koponen, Markku Lähteenvuo, et al.Pageof 8